The fund seeks capital appreciation in the long term by investing in companies across any size outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team invests significantly in domestic and foreign equity securities of companies across m More

The fund seeks capital appreciation in the long term by investing in companies across any size outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

Next, the research team invests significantly in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary that are relevant to the fund’s investment theme of the genomics revolution.

The team favors companies that are focused on extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business.

In selecting securities for the portfolio, the research team prefers companies that are capitalizing on disruptive innovation or that are enabling the further development of a theme in the markets in which they operate.

Also, the research team integrates environmental, social and governance factors as part of its process.

In addition, the team employs both top-down and bottom-up analysis to select investments for the fund.

In its top down approach, the team utilizes the framework of the United Nations Sustainable Development Goals to integrate ESG considerations into its research and investment process.

As part of its bottom up approach, the team evaluates the potential of individual companies, while integrating ESG considerations into that process.

Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.

The portfolio holds between 40 and 60 companies.

However, the fund’s net assets will be invested in equity securities, including common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises.

The fund’s investments in foreign equity securities will be in both developed and emerging markets.

Additionally, the fund will be concentrated in securities of issuers having their principal business activities in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry.

Other industries in the health care sector include medical laboratories and research and drug manufacturers.

The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts and Global Depositary Receipts.

The fund is classified as a non-diversified investment company, which means that it may invest a high percentage of its assets in a limited number of issuers.